Benchmarking Biomarkers In Clinical Trials
Executive Summary
Where does pharma stand in its use of biomarkers to assess clinical trial efficacy and safety or to preselect patients? A new report by Informa establishes a benchmark for measuring biomarker adoption and impact.
You may also be interested in...
IO Driving Surge In Number, Complexity Of Cancer Trials
Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)